Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Medical Technology Advisor Gottlieb Returning To AEI

This article was originally published in The Pink Sheet Daily

Executive Summary

He will serve as a fellow at the American Enterprise Institute and plans to launch a new publication in conjunction with Forbes on emerging medical technology. Gottlieb was an AEI fellow prior to joining FDA, where he served as medical policy development director before leaving for CMS.

You may also be interested in...



CMS Ready To Unveil "Council For Technology & Innovation"

The council will establish two working groups: the "Better Evidence" group will focus on improving clinical data available for coverage decisions and the "Effective Innovation" group will develop ways to improve the efficiency of the coverage decision process. CMS' Herbert Kuhn and Sean Tunis will co-chair the council.

FDA Brain Drain? Four Agency Staffers Join McClellan At CMS

The Centers for Medicare & Medicaid Services administrator is surrounding himself with some of his closest advisors as CMS gears up to implement the Medicare Rx drug benefit. None of the four staffers had line operation functions at FDA.

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel